| چکیده انگلیسی مقاله |
Background: Dual anti-HER2 blockade with trastuzumab plus pertuzumab combined with a taxane is the first-line treatment for metastatic HER2-positive breast cancer. However, little evidence is available on its efficacy and safety in sub-Saharan African populations. We aimed to report the effect of dual anti-HER2 blockade in Côte d’Ivoire on a cohort of patients followed up for HER2-positive metastatic breast cancer. Methods: We conducted a retrospective analytical cohort study of female patients with HER2-positive metastatic breast cancer who were followed up in the public cancer management hospitals in Côte d’Ivoire (Treichville University Hospital Center and the National Center for Radiation Oncology) over a 2-year period from January 1, 2021, to December 31, 2022. The outcome of interest was progression-free survival, estimated by the Kaplan-Meier method. A univariable Cox regression model was used to test factors associated with progression-free survival. Variables with P < 0.10 were included in the multivariable model. Results: We collected data on 30 patients. The median age was 47.2 years (interquartile range, 25 years). Common metastatic sites were the lung (63.3%), pleura (20.0%), liver (20.0%), bone (16.7%), and brain (6.7%). The most frequent adverse events were anemia (93.3%) and neutropenia (73.3%). The objective response rate was 60.0%. The median progression-free survival was 15.3 months. Median overall survival was not reached. Factors associated with better progression-free survival were the absence of brain metastasis (P = 0.003) and the administration of dual anti-HER2 blockade as first-line therapy (P = 0.005). Conclusion: Dual anti-HER2 blockade showed therapeutic activity in terms of objective response, progression-free survival, and tolerability. |
| نویسندگان مقاله |
| Kouame Konan Yvon Kouassi
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire; Medical Oncology Department of the Bouaké University Hospital Center, Abidjan, Côte d’Ivoire; Félix Houphouët Boigny University, Abidjan, Côte d’Ivoire
| Bitti Adde Odo
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire; Medical Oncology Department of the Bouaké University Hospital Center, Abidjan, Côte d’Ivoire; Félix Houphouët Boigny University, Abidjan, Côte d’Ivoire
| Yenahaban Lazare Toure
Medical Oncology Department of the Bouaké University Hospital Center, Abidjan, Côte d’Ivoire; Félix Houphouët Boigny University, Abidjan, Côte d’Ivoire; Alassane Ouattara University, Bouaké, Côte d’Ivoire
| Amougou Felix Mbarga
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire
| Femi Perez Odidi
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire
| Petiori Gningayou Laurence Toure Spouse Kamara
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire; Medical Oncology Department of the Bouaké University Hospital Center, Abidjan, Côte d’Ivoire; Félix Houphouët Boigny University, Abidjan, Côte d’Ivoire
| Mohamed Kassir Agnidé Madiou
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire
| N’Guessan Manlan Prosper Mébiala
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire; Medical Oncology Department of the Bouaké University Hospital Center, Abidjan, Côte d’Ivoire; Félix Houphouët Boigny University, Abidjan, Côte d’Ivoire
| Audrey Fleur Sessegnon
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire; Medical Oncology Department of the Bouaké University Hospital Center, Abidjan, Côte d’Ivoire; Félix Houphouët Boigny University, Abidjan, Côte d’Ivoire
| Akissi Marie Barbara Yvonne Nogbou
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire
| Moctar Toure
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire; Medical Oncology Department of the Bouaké University Hospital Center, Abidjan, Côte d’Ivoire; Félix Houphouët Boigny University, Abidjan, Côte d’Ivoire
| Innocent Adoubi
Medical Oncology Department of the Treichville University Hospital Center, Abidjan, Côte d’Ivoire; Félix Houphouët Boigny University, Abidjan, Côte d’Ivoire; National Cancer Control Program, Abidjan, Côte d’Ivoire
|